Latest News

Germany lagging behind in stem cell research

Neural stem cell. Confocal microscopy image illustrating long-range organization for neurons (green) and nuclei (blue) within a developing neural construct. © University of Wisconsin, Photo: Michael Schwartz.


by tg

A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.

According to a White Paper from experts of the German Stem Cell Network (GSCN), investments into stem cell research in Germany initially increased from €58.8m in 2009 to €71.3m in 2011 but then permanently decreased to €54.9m by 2014. In contrast, the UK government almost doubled the amount of money into stem cell research from €82.4m in the fiscal year 2010/11 to €169.2m in 2014/15. Whilst investments of the Japanese funding bodies remained constant (€65.1m) from 2009-2012, they rose to €91.2m in 2014 due to the new focus of government investment into applications of induced pluripotent cells (iPSCs).

Most funding, however, is available in the US: the NIH has increased its annual budget for stem cell research from €1,070m in 2011 to €1.400m in 2015. However, funding of the state of New York and the Californian CIRM added €40.5m and €270m annually from 2011-2015 to that amount, respectively.

The GSCN said that Germany ranked last in funding with €0.68/citizen behind Japan (0.72), Sweden (1.02), the UK (2.62), and the US (4.36). The European Federation of Pharmaceutical Industry Associations (EFPIA) and the European Commission have put a focus on creating stem cell resources for secondary drug screening within the Innovative Medicines Initiative. They underline the need for improved funding to exploit the potential of stem cells in drug screening and regenerative medicine.

Chong Kun Dang Pharm licences Synaffix ADC platform

Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

First hints for leukopenia diagnostic in MS

Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

500 experts at the 7th AMR Conference in Basel

That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

BioNTech bags Instadeep for £562m

According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

European VCs join US$105m financing of US Mediar Thx

Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody

With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Ultra-processed foods increase risk for cancer

According to a long-term data from the UK biobank, high consumption of ultra-processed foods are linked to bad health outcomes such as diabetes,-...